[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

恩扎鲁胺 前列腺癌 医学 多西紫杉醇 肿瘤科 临床终点 醋酸阿比特龙酯 内科学 泌尿科 癌症 临床试验 雄激素剥夺疗法 雄激素受体
作者
Louise Emmett,Shalini Subramaniam,Megan Crumbaker,Andrew Dang Khai Nguyen,Anthony Michael Joshua,Andrew James Weickhardt,Sze-Ting Lee,Siobhan Su Wan Ng,Roslyn J. Francis,Jeffrey C.H. Goh,David A. Pattison,Thean Hsiang Tan,Ian David Kirkwood,Craig A. Gedye,Natalie K. Rutherford,Shahneen Kaur Sandhu,Aravind S. Ravi Kumar,David William Pook,Shakher Ramdave,David P. Nadebaum
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:25 (5): 563-571 被引量:209
标识
DOI:10.1016/s1470-2045(24)00135-9
摘要

Background Enzalutamide and lutetium-177 [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 both improve overall survival in patients with metastatic castration-resistant prostate cancer. Androgen and PSMA receptors have a close intracellular relationship, with data suggesting complementary benefit if targeted concurrently. In this study, we assessed the activity and safety of enzalutamide plus adaptive-dosed [177Lu]Lu-PSMA-617 versus enzalutamide alone as first-line treatment for metastatic castration-resistant prostate cancer. Methods ENZA-p was an open-label, randomised, controlled phase 2 trial done at 15 hospitals in Australia. Participants were men aged 18 years or older with metastatic castration-resistant prostate cancer not previously treated with docetaxel or androgen receptor pathway inhibitors for metastatic castration-resistant prostate cancer, gallium-68 [68Ga]Ga-PSMA-PET-CT (PSMA-PET-CT) positive disease, Eastern Cooperative Oncology Group performance status of 0–2, and at least two risk factors for early progression on enzalutamide. Participants were randomly assigned (1:1) by a centralised, web-based system using minimisation with a random component to stratify for study site, disease burden, use of early docetaxel, and previous treatment with abiraterone acetate. Patients were either given oral enzalutamide 160 mg daily alone or with adaptive-dosed (two or four doses) intravenous 7·5 GBq [177Lu]Lu-PSMA-617 every 6–8 weeks dependent on an interim PSMA-PET-CT (week 12). The primary endpoint was prostate-specific antigen (PSA) progression-free survival, defined as the interval from the date of randomisation to the date of first evidence of PSA progression, commencement of non-protocol anticancer therapy, or death. The analysis was done in the intention-to-treat population, using stratified Cox proportional hazards regression. This trial is registered with ClinicalTrials.gov, NCT04419402, and participant follow-up is ongoing. Findings 162 participants were randomly assigned between Aug 17, 2020, and July 26, 2022. 83 men were assigned to the enzalutamide plus [177Lu]Lu-PSMA-617 group, and 79 were assigned to the enzalutamide group. Median follow-up in this interim analysis was 20 months (IQR 18–21), with 32 (39%) of 83 patients in the enzalutamide plus [177Lu]Lu-PSMA-617 group and 16 (20%) of 79 patients in the enzalutamide group remaining on treatment at the data cutoff date. Median age was 71 years (IQR 64–76). Median PSA progression-free survival was 13·0 months (95% CI 11·0–17·0) in the enzalutamide plus [177Lu]Lu-PSMA-617 group and 7·8 months (95% CI 4·3–11·0) in the enzalutamide group (hazard ratio 0·43, 95% CI 0·29–0·63, p<0·0001). The most common adverse events (all grades) were fatigue (61 [75%] of 81 patients), nausea (38 [47%]), and dry mouth (32 [40%]) in the enzalutamide plus [177Lu]Lu-PSMA-617 group and fatigue (55 [70%] of 79), nausea (21 [27%]), and constipation (18 [23%]) in the enzalutamide group. Grade 3–5 adverse events occurred in 32 (40%) of 81 patients in the enzalutamide plus [177Lu]Lu-PSMA-617 group and 32 (41%) of 79 patients in the enzalutamide group. Grade 3 events that occurred only in the enzalutamide plus [177Lu]Lu-PSMA-617 group included anaemia (three [4%] of 81 participants) and decreased platelet count (one [1%] participant). No grade 4 or 5 events were attributed to treatment on central review in either group. Interpretation The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved PSA progression-free survival providing evidence of enhanced anticancer activity in patients with metastatic castration-resistant prostate cancer with risk factors for early progression on enzalutamide and warrants further evaluation of the combination more broadly in metastatic prostate cancer. Funding Prostate Cancer Research Alliance (Movember and Australian Federal Government), St Vincent's Clinic Foundation, GenesisCare, Roy Morgan Research, and Endocyte (a Novartis company).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zz完成签到,获得积分10
1秒前
3秒前
领导范儿的应助被zyc采纳,获得10
3秒前
快别闹了发布了新的文献求助10
4秒前
5秒前
传奇3的应助被桃子汽水采纳,获得10
6秒前
标致的问芙完成签到 ,获得积分10
6秒前
小蝴蝶发布了新的文献求助10
7秒前
7秒前
wuwu完成签到,获得积分10
7秒前
冷静完成签到,获得积分10
7秒前
笑嘻嘻发布了新的文献求助10
7秒前
9秒前
李健的应助被武陵济世采纳,获得100
9秒前
9秒前
Redream发布了新的文献求助10
11秒前
木木夕发布了新的文献求助10
11秒前
11秒前
11秒前
lzy完成签到,获得积分10
12秒前
CodeCraft的应助被ly采纳,获得10
13秒前
大点搞完成签到 ,获得积分10
15秒前
junjie发布了新的文献求助10
15秒前
深情安青的应助被Niya采纳,获得10
16秒前
17秒前
昏睡的冰枫完成签到 ,获得积分10
18秒前
zyc发布了新的文献求助10
18秒前
布二发布了新的文献求助10
19秒前
19秒前
SciGPT的应助被小蝴蝶采纳,获得10
20秒前
20秒前
20秒前
22秒前
22秒前
23秒前
天才抱妹噜完成签到 ,获得积分10
23秒前
123完成签到,获得积分10
23秒前
orixero的应助被ggk采纳,获得10
24秒前
科研通AI6.4的应助被王宇洁采纳,获得10
24秒前
Akim的应助被ZY采纳,获得10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183739
求助须知:如何正确求助?哪些是违规求助? 9572996
关于积分的说明 21828615
捐赠科研通 7780904
什么是DOI,文献DOI怎么找? 3434101
关于科研通互助平台的介绍 2558294
邀请新用户注册赠送积分活动 2480564